Join us on 12-15-2022 for a live seminar about RNA SEQ

Click Here

Keyway TCR Mimic Discovery Webinar

Join our Webinar Tuesday February 14th at 11:30am ET
Or register to receive the recording if you can’t make it live

TCR mimics (TCRm) and engineered TCRs enable drug developers to work against the vast space of intracellular proteins (>70% of the human proteome) that have not been addressed by conventional cancer immunotherapies. Despite tremendous potential therapeutic values, the discovery of highly specific TCRm and TCR-based therapeutics remains a challenge for many due to inaccessibility to the required foundational technologies. Alloy’s Keyway TCR Discovery group provides comprehensive proprietary technology and capabilities for the end-to-end discovery of these modalities. In this webinar, leading scientists at the helm of Keyway TCRm Discovery campaigns will present:
 
 
1. An overview of common challenges to intracellular protein-targeting drug discovery
2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities
3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target
 
Join us for an informative discussion, and be sure to bring your questions. 
Name(Required)
Email(Required)

Access the Webinar Recording 

Thanks for your interest in our recent Keyway TCRm Discovery webinar,  Increasing Target Specificity and Tackling Intracellular Targets for TCRm Therapeutics Development with Keyway’s TCRm Discovery Offering. In it, the team at the helm of our TCR mimic discovery campaigns shared:

1. An overview of common challenges to intracellular protein-targeting drug discovery
2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities
3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target

   

Upon filling out this form, you will receive an email with a link to the webinar recording. 

Email(Required)

Webinar speakers

DONGXING ZHA, PHD
LUCY LIU, PHD
JENNIFER WATKINS-YOON, PHD
JAAFAR HAIDAR, PHD
WEI-CHENG LU

Discover TCR mimics that target pMHCs in a highly specific manner

Keyway™ TCR Discovery is the first and only fully integrated discovery service for soluble therapeutics against peptide-MHCs. Keyway has developed a proprietary platform that you can access through our Discovery Services for TCRm today and engineered TCRs by the end of 2023. Keyway TCRm encompasses proprietary antibody-like bispecific formats for simultaneous effector cell engagement and target engagement.

TCR drug discovery services
Accept Privacy Settings Here
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please read and Privacy Policy
Youtube
Consent to display content from - Youtube
Vimeo
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google
Spotify
Consent to display content from - Spotify
Sound Cloud
Consent to display content from - Sound